← Back to Search

Peptide Dimer

KSP/QRH dimer for Bile Duct Cancer

Phase 1
Waitlist Available
Led By Danielle Kim Turgeon, MD
Research Sponsored by Danielle Kim Turgeon
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during and immediately after procedure, generally no more than 2 hours
Awards & highlights

Study Summary

This trial is testing a new technology to more accurately detect cholangiocarcinoma, a cancer of the bile ducts. The new method uses a fluorescent-labeled peptide dimer, which is a molecule that binds to specific biomarkers for the disease. The dimer is applied topically, and then the patient undergoes a medical procedure called an ERCP, which uses an endoscope to take pictures of the inside of the bile ducts. The pictures are then analyzed to look for the presence of the dimer, which would indicate the presence of cancer. The trial is currently in Phase 1B,

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during and immediately after procedure, generally no more than 2 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and during and immediately after procedure, generally no more than 2 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Contrast in Cell Fluorescence

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dimer Application with SFE imagingExperimental Treatment1 Intervention
Subjects having a standard-of-care ERCP will have the dimer sprayed on an area of interest in the bile duct and images taken with the SFE.

Find a Location

Who is running the clinical trial?

Danielle Kim TurgeonLead Sponsor
3 Previous Clinical Trials
93 Total Patients Enrolled
Danielle Kim Turgeon, MD4.18 ReviewsPrincipal Investigator - University of Michigan
University of Michigan
3 Previous Clinical Trials
15,115 Total Patients Enrolled
5Patient Review
My father passed from Colon Cancer. There is NO ONE else I would trust other than Dr Turgeon to treat my high risk case. Her bedside manner is that of expert, friend, and pure comfort. I travelled from Shelby Township to U of M , and she is worth it! I can't explain how relieved I am knowing this woman genuinely cares about me and my well being. God Bless Dr. Turgeon....

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer
Danielle Kim Turgeon 2020. "Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04304781.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top